Anavex Joins ACCESS-AD, a Major Initiative Funded by the European Commission Through the Clinical Evaluation of Blarcamesine as Part of a Precision Medicine Approach in Alzheimer’s Disease

Anavex Life Sciences Corp Today, January 13, 2026, Anavex Life Sciences Corp. ( AVXL ) announced its participation as a key industry partner in ACCESS-AD, a major new European initiative designed to a...